{
    "Trade/Device Name(s)": [
        "CR3 Keyless Split Sample Cup Morphine \u2013 Methamphetamine"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K150602",
    "Predicate Device Reference 510(k) Number(s)": [
        "K142580"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DNK",
        "LAF"
    ],
    "Summary Letter Date": "March 3, 2015",
    "Summary Letter Received Date": "March 10, 2015",
    "Submission Date": "March 31, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.3640",
        "21 CFR 862.3610"
    ],
    "Regulation Name(s)": [
        "Morphine test system",
        "Methamphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Morphine",
        "Methamphetamine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Cup"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow"
    ],
    "Methodologies": [
        "Competitive binding",
        "Antigen-antibody immunochemistry",
        "Qualitative detection"
    ],
    "Submission Type(s)": [
        "Test",
        "Cup"
    ],
    "Document Summary": "FDA 510(k) summary for CR3 Keyless Split Sample Cup Morphine\u2013Methamphetamine rapid lateral flow immunoassay for qualitative urine detection",
    "Indications for Use Summary": "Rapid qualitative detection of morphine and methamphetamine in human urine at cutoff concentrations of 300 ng/mL and 1000 ng/mL respectively; intended for over-the-counter and prescription use, provides preliminary results requiring laboratory confirmation for positives",
    "fda_folder": "Toxicology"
}